Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VM-1500A-LAI Dose Selection in HIV-1 Patients
NCT05163535Phase 2Completed
- Sponsor
- Viriom Inc
- Start
- Jan 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of depulfavirine long-acting injectable in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Viriom Inc. Started Jan 2021; status: completed.
02
Drugs
depulfavirine long-acting injectable
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT05163535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05163535.